- Home
- AEON vs ACHL Comparison
AEON vs ACHL Comparison
Compare AEON & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- ACHL
- Stock Information
- Founded
- AEON N/A
- ACHL 2016
- Country
- AEON United States
- ACHL United Kingdom
- Employees
- AEON N/A
- ACHL N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEON Health Care
- ACHL Health Care
- Exchange
- AEON Nasdaq
- ACHL Nasdaq
- Market Cap
- AEON 36.4M
- ACHL 40.4M
- IPO Year
- AEON N/A
- ACHL 2021
- Fundamental
- Price
- AEON $0.61
- ACHL $1.05
- Analyst Decision
- AEON Strong Buy
- ACHL Hold
- Analyst Count
- AEON 1
- ACHL 3
- Target Price
- AEON $5.00
- ACHL $2.83
- AVG Volume (30 Days)
- AEON 106.3K
- ACHL 142.6K
- Earning Date
- AEON 11-13-2024
- ACHL 11-14-2024
- Dividend Yield
- AEON N/A
- ACHL N/A
- EPS Growth
- AEON N/A
- ACHL N/A
- EPS
- AEON N/A
- ACHL N/A
- Revenue
- AEON N/A
- ACHL N/A
- Revenue This Year
- AEON N/A
- ACHL N/A
- Revenue Next Year
- AEON N/A
- ACHL N/A
- P/E Ratio
- AEON N/A
- ACHL N/A
- Revenue Growth
- AEON N/A
- ACHL N/A
- 52 Week Low
- AEON $0.60
- ACHL $0.63
- 52 Week High
- AEON $17.17
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- AEON 28.55
- ACHL 60.22
- Support Level
- AEON $0.60
- ACHL $0.99
- Resistance Level
- AEON $0.88
- ACHL $1.12
- Average True Range (ATR)
- AEON 0.07
- ACHL 0.04
- MACD
- AEON -0.03
- ACHL -0.00
- Stochastic Oscillator
- AEON 2.62
- ACHL 54.84
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.